Literature DB >> 17326667

Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family.

Stefan K Nilsson1, Aivar Lookene, Jennifer A Beckstead, Jørgen Gliemann, Robert O Ryan, Gunilla Olivecrona.   

Abstract

Apolipoprotein A-V is a potent modulator of plasma triacylglycerol levels. To investigate the molecular basis for this phenomenon we explored the ability of apolipoprotein A-V, in most experiments complexed to disks of dimyristoylphosphatidylcholine, to interact with two members of the low density lipoprotein receptor family, the low density lipoprotein receptor-related protein and the mosaic type-1 receptor, SorLA. Experiments using surface plasmon resonance showed specific binding of both free and lipid-bound apolipoprotein A-V to both receptors. The binding was calcium dependent and was inhibited by the receptor associated protein, a known ligand for members of the low density lipoprotein receptor family. Preincubation with heparin decreased the receptor binding of apolipoprotein A-V, indicating that overlap exists between the recognition sites for these receptors and for heparin. A double mutant, apolipoprotein A-V (Arg210Glu/Lys211Gln), showed decreased binding to heparin and decreased ability to bind the low density lipoprotein receptor-related protein. Association of apolipoprotein A-V with the low density lipoprotein receptor-related protein or SorLA resulted in enhanced binding of human chylomicrons to receptor-covered sensor chips. Our results indicate that apolipoprotein A-V may influence plasma lipid homeostasis by enhancing receptor-mediated endocytosis of triacylglycerol-rich lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326667     DOI: 10.1021/bi7000533

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy.

Authors:  Abdolkarim Mahrooz; Mehryar Zargari; Vahid Ansari; Atieh Makhlough; Mohammad-Bagher Hashemi-Sooteh
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  The Vps10p-domain receptor family.

Authors:  Guido Hermey
Journal:  Cell Mol Life Sci       Date:  2009-05-12       Impact factor: 9.261

3.  Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.

Authors:  Qin Feng; Susan S Baker; Wensheng Liu; Ricardo A Arbizu; Ghanim Aljomah; Maan Khatib; Colleen A Nugent; Robert D Baker; Trudy M Forte; Yiyang Hu; Lixin Zhu
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

4.  Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants.

Authors:  Kasuen Wong-Mauldin; Vincent Raussens; Trudy M Forte; Robert O Ryan
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 5.  Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact.

Authors:  Montse Guardiola; Josep Ribalta
Journal:  Curr Atheroscler Rep       Date:  2017-07       Impact factor: 5.113

Review 6.  Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.

Authors:  Jaroslav A Hubacek
Journal:  Gene       Date:  2016-08-02       Impact factor: 3.688

7.  APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.

Authors:  Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet
Journal:  J Nutr       Date:  2011-01-05       Impact factor: 4.798

8.  Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.

Authors:  S F C Vaessen; G M Dallinga-Thie; C J D Ross; L J Splint; L W Castellani; P C N Rensen; M R Hayden; F G Schaap; J A Kuivenhoven
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

9.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

10.  Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

Authors:  Xian-sheng Huang; Shui-ping Zhao; Lin Bai; Min Hu; Wang Zhao; Qian Zhang
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.